Express News | 'Biogen Is Pursuing More Dealmaking This Year, With Plans To Spend Up To $8B' - Endpoint News

BenzingaJun 27 11:39 ET

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

NOVATO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare

GlobeNewswireJun 20 16:30 ET

Piper Sandler Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $135

Piper Sandler analyst Christopher Raymond maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $135.According to TipRanks data, the analyst has a success

moomoo NewsJun 20 08:31 ET · Ratings

TD Cowen Maintains Ultragenyx Pharmaceutical(RARE.US) With Buy Rating, Maintains Target Price $61

TD Cowen analyst Yaron Werber maintains $Ultragenyx Pharmaceutical(RARE.US)$ with a buy rating, and maintains the target price at $61.According to TipRanks data, the analyst has a success rate of 0.0%

moomoo NewsJun 17 06:31 ET · Ratings

Why AMMO Shares Are Trading Lower By Over 19%? Here Are Other Stocks Moving In Friday's Mid-Day Session

Shares of AMMO, Inc. (NASDAQ:POWW) fell sharply during Friday's session following fourth-quarter results.AMMO reported a fourth-quarter profit of 1 cent per share, compared to market expectations for

BenzingaJun 14 14:13 ET

Wedbush Adjusts Ultragenyx Pharmaceutical's Price Target to $45 From $48, Keeps Neutral Rating

Ultragenyx Pharmaceutical (RARE) has an average rating of buy and price targets ranging from $45 to $140, according to analysts polled by Capital IQ. Price: 39.15, Change: -3.97, Percent Change: -9.22

MT NewswiresJun 14 11:34 ET